Patient access, triage, and agents
Sully.ai
Healthcare AI-agent platform and documentation API that describes agents for scribing, reception, triage, coding, nursing, interpretation, research, and EHR-connected workflows.
Last updated: June 13, 2026
Back to directoryC the Signs medical AI product profile
AI cancer-detection and clinical decision-support platform that helps clinicians and patients identify cancer risk, choose referral pathways, and surface high-risk patients from records.
Patient access, triage, and agents
Best fit
Organizations evaluating governed cancer-risk and early-detection workflows that must connect symptoms, risk factors, EHR data, patient self-assessment, referral pathways, and local service capacity.
- Primary use case
- AI-supported cancer risk assessment, EHR-integrated pathway guidance, patient self-assessment, population scanning, and referral support
- Audience
- UK primary care teams, NHS commissioners, population-health leaders, cancer pathway teams, and health systems evaluating early-detection workflows
- Risk level
- High
- Pricing signal
- Healthcare organization and NHS deployment terms; verify current regional availability, contract, support, and implementation scope.
- Official sources
- 6 official sources
Compare within workflow: Patient access, triage, and agents · comparison shortlist · source index
Regulatory snapshot
| Status | Vendor-stated UKCA Class I medical device and MHRA-regulated tool; verify current certificate, intended use, and jurisdiction-specific requirements. |
|---|---|
| Review route | UKCA Class I / MHRA medical-device positioning, with NHS clinical-risk and data-security compliance claims from vendor materials. |
| Intended use | Supports healthcare professionals and commissioned services with cancer-risk assessment, pathway guidance, patient self-assessment, and population-level early-detection workflows. |
| Verification note | Confirm the current UKCA/MHRA documentation, DCB0129/060 clinical safety case, local pathway configuration, EHR integration, patient self-assessment claims, and any US or non-UK regulatory status before clinical reliance. |
| Source | www.cthesigns.com / what-we-do |
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating C the Signs as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as high-risk clinical decision support and cancer-pathway software; verify UKCA Class I, MHRA-regulated status, NHS clinical-risk files, intended users, patient self-assessment boundaries, and any non-UK regulatory pathway before deployment. |
|---|---|
| Privacy | Review controller/processor roles, GP or provider data agreements, NHS number use, EHR record access, coded writeback, UK hosting, self-assessment flows, retention, subprocessors, cross-border transfers, and patient-facing consent. |
| Evidence | Use the official research trail as a starting point, then validate sensitivity, tumour-origin prediction, referral burden, stage shift, equity effects, and missed-cancer review against local cancer pathways and population mix. |
| Workflow | Define when the platform runs during consultation, self-assessment, or population scanning; who reviews outputs; how referrals are made; how false positives or missed cases are audited; and how pathway updates are governed. |
Where C the Signs fits
C the Signs describes an AI platform for early cancer detection that uses more than 1,000 validated data points, supports clinician risk assessment and referral in under 60 seconds, integrates with NHS EHRs, scans population records, and provides patient self-assessment. Vendor pages state UKCA Class I medical-device status, NHS clinical-risk and data-security compliance, HIPAA/HITECH positioning, and research pages summarizing real-world cancer-detection studies.
Not for: Standalone cancer diagnosis, emergency triage, consumer use without commissioned pathways, or replacing clinician judgment, specialist referral criteria, diagnostic testing, and local cancer governance.
What to verify before using C the Signs
- Which workflow is in scope: clinician consultation support, patient self-assessment, proactive population scanning, cancer-site prediction, or referral-pathway selection.
- Whether the UKCA Class I medical-device, MHRA, NHS DCB0129/060, NHS DSPT, IM1, FHIR/HL7, HIPAA, HITECH, and accessibility claims apply to the exact deployment region and contract.
- How signs, symptoms, risk factors, coded entries, structured and unstructured EHR data, NHS numbers, patient identifiers, event logs, and self-assessment data are processed, retained, and written back.
- Local performance for sensitivity, tumour-origin prediction, referral conversion, false positives, missed cancers, urgent pathway load, equity impact, language support, and clinician override behavior.
- How clinicians handle outputs that suggest cancer risk, how patients are escalated, and how pathway recommendations are updated when national or local cancer guidance changes.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.cthesigns.com
- www.cthesigns.com / what-we-do
- www.cthesigns.com / research
- www.cthesigns.com / terms-of-use
- www.cthesigns.com / privacy
- www.cthesigns.com / self-assessment-privacy-policy
Related medical AI products
Patient access, triage, and agents
Memora Health
Intelligent care enablement platform for automating patient touchpoints and supporting care teams across longitudinal care journeys.
Patient access, triage, and agents
Ada Health
Clinical AI symptom-assessment and care-navigation platform for digital front door and patient-routing workflows.
Patient access, triage, and agents
Mediktor
Digital triage and AI medical-assistant platform for patient guidance, care routing, and healthcare-organization workflows.